Provided by Tiger Trade Technology Pte. Ltd.

Caribou Biosciences

0.6174
-0.5176-45.60%
Pre-market: 0.5824-0.0350-5.67%06:46 EDT
Volume:37.51M
Turnover:23.23M
Market Cap:66.06M
PE:-0.57
High:0.6700
Open:0.6360
Low:0.5460
Close:1.14
52wk High:3.54
52wk Low:0.5460
Shares:107.00M
Float Shares:102.16M
Volume Ratio:18.97
T/O Rate:36.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0751
EPS(LYR):-1.5900
ROE:-78.27%
ROA:-36.84%
PB:0.67
PE(LYR):-0.39

Loading ...

Caribou Biosciences: Buy Rating Reaffirmed on Advancing Allogeneic CAR-T Pipeline and EHA Data; $6 Price Target Maintained

TIPRANKS
·
Jun 12

Caribou Biosciences presents ANTLER trial results at EHA

TIPRANKS
·
Jun 11

Caribou Biosciences Potential Non-Hodgkin Lymphoma Cell Therapy Shows 'Durable' Responses

MT Newswires Live
·
Jun 11

Caribou Biosciences posts EHA presentation on vispa-cel durability data in B-cell lymphoma trial

Reuters
·
Jun 11

Caribou says off-the-shelf CAR-T vispa-cel posts 82% response rate in second-line LBCL study

Reuters
·
Jun 11

Caribou reports durable responses in phase 1 CaMMouflage trial of CB-011 CAR-T in relapsed multiple myeloma

Reuters
·
Jun 11

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Caribou Biosciences CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

Caribou Biosciences (CRBU) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 27

May 2026's Promising Penny Stocks

Simply Wall St.
·
May 14

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

GlobeNewswire
·
May 14

Caribou Biosciences to present vispa-cel data at EHA annual meeting

Reuters
·
May 12

Caribou Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 11

Caribou Biosciences, Inc. : H.c. Wainwright Raises Target Price to $11 From $9

THOMSON REUTERS
·
May 11

U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla

Reuters
·
May 11

Caribou Biosciences (CRBU) Gets a Buy from Citi

TIPRANKS
·
May 10

Caribou Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 09

Caribou aligns with FDA on ANTLER-3 phase 3 vispa-cel trial design in 2L LBCL

Reuters
·
May 08

Caribou Biosciences Q1 FY26 net loss narrows to $25.09 million; R&D expenses drop to $20.61 million

Reuters
·
May 08

Caribou Biosciences Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
May 07